A (selective) androgen receptor degrader or downregulator (SARD) is a type of drug which interacts with the androgen receptor (AR) such that it causes the AR to be degraded and thus downregulated.
[1] They are under investigation for the treatment of prostate cancer and other androgen-dependent conditions.
[1] As of 2017, dimethylcurcumin (ASC-J9), a SARD, is under development for the treatment of acne vulgaris.
[2] In addition, several PROTACs degraders targeting the androgen receptor have been tested in the clinic: This drug article relating to the genito-urinary system is a stub.
You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.